共 50 条
- [41] Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung CancerACTA MEDICA OKAYAMA, 2021, 75 (01) : 15 - 23Katsui, KuniakiOgata, TakeshiTada, AkihiroSugiyama, SoichiYoshio, KotaroKuroda, MasahiroKiura, KatsuyukiMaeda, YoshinobuToyooka, ShinichiHiraki, TakaoKanazawa, Susumu
- [42] Heart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancerRADIOTHERAPY AND ONCOLOGY, 2020, 152 : 126 - 132Jang, Bum-SupCha, Myung-JinKim, Hak JaeOh, SeilWu, Hong-GyunKim, EunjiKim, Byoung HyuckKim, Jae SikChang, Ji Hyun
- [43] International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung CancerJAMA NETWORK OPEN, 2024, 7 (05) : E2413938Kareff, Samuel A.Han, SunwooHaaland, BenjaminJani, Chinmay J.Kohli, RheaAguiar Jr, Pedro NazarethHuang, YiqingSoo, Ross A.Rodriguez-Perez, AngelGarcia-Foncillas, JesusDomine, Manuelde Lima Lopes, Gilberto
- [44] Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancerLUNG CANCER, 2023, 182Dickhoff, C.Unal, S.Heineman, D. J.Winkelman, J. A.Braun, J.Bahce, I.van Dorp, M.Senan, S.Dahele, M.
- [45] Prospective evaluation of outcome and toxicity of durvalumab treatment after chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) patientsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Kaesmann, LukasTaugner, JulianEze, ChukwukaRoengvoraphoj, OlarnBelka, ClausManapov, Farkhad
- [46] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after ChemoradiotherapyJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S294 - S295Oh, H. -J.Park, C. -K.Kim, Y. -C.Kim, Y. -H.Ahn, S. -J.Jeong, W. G.Lee, J. Y.Lee, J. C.Choi, C. M.Ji, W.Song, S. Y.Choi, J.Lee, S. Y.Kim, H.Lee, S. Y.Park, J.Yoon, S. H.Joo, J. H.Oh, I. -J.
- [47] Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancerJOURNAL OF RADIATION RESEARCH, 2023, 64 (01) : 142 - 153Kishi, NorikoMatsuo, YukinoriShintani, TakashiOgura, MasakazuMitsuyoshi, TakamasaAraki, NorioFujii, KotaOkumura, SetsukoNakamatsu, KiyoshiKishi, TakahiroAtsuta, TomokoSakamoto, TakashiOhtsu, ShujiKatagiri, TomohiroNarabayashi, MasaruFujishiro, SatsukiIizuka, YusukeOzasa, HiroakiHirai, ToyohiroMizowaki, Takashi
- [48] Durvalumab after concurrent chemoradiotherapy in a patient with chemotherapy-resistant unresectable stage III non-small cell lung cancer: a case reportANNALS OF PALLIATIVE MEDICINE, 2020, 9 (04) : 2375 - 2380Zhang, TaoWu, YuqiZheng, ShanCheng, GuoweiHe, XianglingBi, Nan
- [49] Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancerTRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 555 - 562Hamada, AkiraSoh, JunichiMitsudomi, Tetsuya
- [50] Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysisANNALS OF ONCOLOGY, 2019, 30Taugner, J.Kaesmann, L.Eze, C.Dantes, M.Roengvoraphoj, O.Gennen, K.Karin, M.Tufman, A.Belka, C.Manapov, F.